MILWAUKEE, March 13, 2023 /PRNewswire/ -- Ademi LLP is investigating Seagen SGEN for possible breaches of fiduciary duty and other violations of law in its transaction with Pfizer.
Click here to learn how to join the action https://www.ademilaw.com/case/seagen-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Ademi LLP alleges Seagen's financial outlook and prospects are excellent and yet Seagens shareholders are expected to receive only $229 in cash per Seagen share for a total enterprise value of $43 billion. The transaction agreement unreasonably limits competing bids for Seagen by imposing a significant penalty if Seagen accepts a superior bid. Seagen insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Seagen's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Seagen.
If you own Seagen common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/seagen-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
